Measles and rubella elimination country profile Sweden



Measles elimination status

2016 eliminated 2017 eliminated

Source: European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/7thrvo

Measles and rubella surveillance

National case-based surveillance for Lab confirmation for diagnosis of

Source: WHO/UNICEF Joint Reporting Form on Immunization, 2017

Measles and rubella immunization schedule, 2017

	Vaccine	Schedule	Year of int	roduction				
MCV1	MMR	18 months	MCV2	1982				
MCV2	MMR	6-8 years	RCV	1974* 1982**				
N	Measles vaccination in school							

Source: Immunization schedule, WHO, Data and Statistics, Immunization Monitoring and Surveillance

(http://www.who.int/immunization/monitoring_surveillance/data/en/)
MMR = measles-mumps-rubella vaccine; MCVI = first dose measles-containing vaccine;

MCV2 = second dose measles-containing vaccine; RCV = rubella-containing vaccir

* girls only; ** all children

Definition used for an outbreak

2 or more cases which are temporarily related and epidemiologically or virologically linked, or both



Source: Measles and rubella elimination Annual Status Update report, 2017

Rubella elimination status




Source: European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/7thrvo

Demographic information, 2017

Total population	9 910 701
< 1 year old	118 965
< 5 years old	589 973

Source: World Population Prospects: The 2017 Revision, New York, United Nations

Measles and rubella cases and immunization coverage, 2008-2017



Source: Disease incidence and immunization coverage (WUENIC), WHO, Data and Statistics,


Immunization Monitoring and Surveillance

(http://www.who.int/immunization/monitoring_surveillance/data/en/)

MCV1 = first dose of measles-containing vaccine

MCV2= second dose of measles-containing vaccine

Confirmed measles cases by month of onset, 2013-2017




Source: CISID 2017




Measles and rubella elimination country profile Sweden



Measles cases by first subnational level, 2017




Measles genotypes by first subnational level, 2017



Note: The dots in the maps are placed randomly within the administrative regions.

Map disclaimer: The boundaries and names shown and the designations used on the maps do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Measles cases by age group and vaccination status, 2017



Source: Measles and rubella elimination Annual Status Update report, 2017

Sources of infection, 2017

	Measles	Rubella
Imported	11	0
Import-related	28	0
Unknown/ Not reported	2	0
Endemic	0	0

Source: Measles and rubella elimination Annual Status Update report, 2017

Information on CRS, 2017



Source: Measles and rubella elimination Annual Status Update report, 2017 CRS = congenital rubella syndrome

Measles and rubella elimination country profile Sweden



Measles incidence, epidemiologic and virologic characteristics, 2013-2017

	Suspected		Confirmed m	neasles cases		Discarded as	Measles	Genotypes	
	cases	Laboratory	Epi- linked	linked Clinically Total non-measles	incidence	detected			
2013	ND	50	1	0	51	ND	5.3	B3, D8	
2014	ND	26	0	0	26	ND	2.7	B3, D8	
2015	ND	21	1	0	22	ND	2.2	D8	
2016	ND	3	0	0	3	ND	0.3	B3, D8	
2017	ND	41	0	0	41	ND	3	B3,D8	

ND = Data not available: NA= Not applicable

Rubella incidence, epidemiologic and virologic characteristics, 2013-2017

	Suspected		Confirmed rubella cases				Rubella	Genotypes
	cases	Laboratory	Epi- linked	Clinically	Total		incidence	detected
2013	ND	0	0	0	0	ND	0	NA
2014	ND	0	0	0	0	ND	0	NA
2015	ND	0	0	0	0	ND	0	NA
2016	ND	0	0	0	0	ND	0	NA
2017	ND	0	0	0	0	ND	0	NA

urce: Measles and rubella elimination Annual Status Update report, 2013-2017

Incidence calculated per 1 million population ND = Data not available: NA= Not applicable

Measles surveillance and laboratory performance indicators, 2013-2017

	Discarded non- measles rate	% 1st sub- national unit with ≥ 2 discarded cases	% cases with adequate laboratory investigation	% origin of infection known	# specimen tested for measles	% positive for measles	Rate of viral detection	% WHO and proficient labs
2013	ND	ND	ND	90%	ND	ND	100%	100%
2014	ND	ND	ND	73%	ND	ND	100%	100%
2015	ND	ND	ND	86%	ND	ND	100%	100%
2016	ND	ND	ND	100%	ND	ND	NA	100%
2017	ND	ND	ND	95%	ND	ND	100%	100%

ND = Data not available; NA= Not applicable

A proficient laboratory is WHO accredited and/or has an established quality assurance programme with oversight

Rubella surveillance and laboratory performance indicators,

	Discarded non- rubella rate	% 1st sub- national unit with ≥ 2 discarded cases	% cases with adequate laboratory investigtion	% origin of infection known	# specimen tested for rubella	% positive for rubella	Rate of viral detection	% WHO and proficient labs
2013	ND	ND	ND	NA	ND	ND	NA	ND
2014	ND	ND	ND	NA	ND	ND	NA	ND
2015	ND	ND	ND	NA	ND	ND	NA	ND
2016	ND	ND	ND	NA	ND	ND	NA	100%
2017	ND	ND	ND	NA	ND	ND	NA	100%

Source: ASU 2013-2017 and communication with the country ND = Data not available; NA= Not applicable

A proficient laboratory is WHO accredited and/or has an established quality assurance programme with oversight by a WHO accredited laboratory

RVC comments, based on 2017 reporting

The Regional Verification Commission for Measles and Rubella Elimination (RVC) concluded that endemic transmission of both measles and rubella remained interrupted in Sweden in 2017 and confirmed that measles and rubella elimination has been sustained.

Source: European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/7thrvc

Surveillance performance indicators and targets

- a. Rate of discarded cases: at least 2 discarded measles or rubella cases per 100 000 population
- b. % cases with adequate laboratory investigation: ≥ 80%
- c. % origin of infection known: ≥ 80%
- d. Rate of viral detection: ≥ 80%

